Development of molecular assays based on epigenetic biomarkers which allow early and reliable cancer diagnostics – this is the intention of oncgnostics!
Our products should allow an early detection of diseases to substantially inprove therapy success. Notice: if detected early, almost all cancer cases are curable.
If you would like us to keep you informed about news related to our company, please sign in for our quarterly newsletter.
oncgnostics GmbH
https://www.oncgnostics.com/wp-content/uploads/2021/06/210602_Pressetermin_Jena_TV_11.jpg
321
845
TowerPR
https://www.oncgnostics.com/wp-content/uploads/2015/03/oncgnostics-logo1-300x138.png
TowerPR2021-06-08 15:00:572021-06-08 15:00:57We’ve moved: More space for new challenges
Andrey_Popov/Shutterstock.com
https://www.oncgnostics.com/wp-content/uploads/2020/03/shutterstock_639110809_web.jpg
1280
1920
TowerPR
https://www.oncgnostics.com/wp-content/uploads/2015/03/oncgnostics-logo1-300x138.png
TowerPR2021-04-20 13:31:452021-04-20 13:31:45Study „OroCa-Graz“ – Study on Head-and-Neck tumors: oncgnostics GmbH cooperates with the Medical University of Graz
oncgnostics GmbH Susann Nuernberger / EUROIMMUN Medizinische Labordiagnostika AG
https://www.oncgnostics.com/wp-content/uploads/2021/03/210315_Vertrag_Euroimmun_Website.jpg
321
845
TowerPR
https://www.oncgnostics.com/wp-content/uploads/2015/03/oncgnostics-logo1-300x138.png
TowerPR2021-03-25 09:44:542021-03-25 09:44:54International sales partnership with EUROIMMUN for Distribution of GynTectOur fist product, GynTect®, enables reliable and fast diagnosis of cervical cancer and pre-cancerous stages.
Video in German.
